🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The Biotech Paradox of 2020: A Year In Review The striking dichotomy of simultaneously experiencing agonizing tragedy alongside buoyant optimism. Surprisingly, in many ways 2020 was actually the best year ever for biotech. lifescivc.com/2021/01/the-bi…

Learn how Life Science Cares Boston leverages the life science industry to reduce the effects of poverty and is expanding its footprint in #biotech hubs across the US. Join their panel discussion today at 5:20 pm ET at bit.ly/LSCatJPM (#JPMHC21 registration NOT required!) #LSCImpact

“Proud to work with an A+ team committed to innovating in #neuroscience & to delivering new therapies for patients with #neurodegenerativediseases. We're excited to build Vigil from the ground up. I expect great things from our team in the year ahead.” #vigilantforyou

"To be a member of the Vigil team and working alongside such dedicated and capable drug developers, all with a common goal to improve lives for patients suffering from #neurodegenerativediseases, is both an honor and a privilege." #vigilantforyou

Minhas et al.’s recent nature publication on restoring #microglia metabolism in mice suggests further exploration of microglia metabolic dysfunction in AD caused by #TREM2 deficiency go.nature.com/3p8OzGM #microgliaMonday #vigilantforyou

“It is clear working alongside this team that this group is dedicated to creating partnerships with the patients, caregivers and regulators, while ensuring expertise and high-quality data is at the forefront of development.” #vigilantforyou

Honored to join the panel for The Flywheel at Northpond Ventures ’s Inaugural Conference. Vigil's Wheel is built around the patients. "That is our why, what brings us to work every day. The vision of bringing novel therapeutics to patients." -Ivana_VigilNeuroCEO #vigilantforyou #lifesciences

Vigil is proud to recognize and celebrate international #WomenInScience Day. Today we celebrate #WomenInSTEM, including our very own team members, for pushing boundaries and inspiring the next generation of women and girls in science.

In a recent Neuron publication, Safaiyan et al. identify white matter-associated #microglia (WAM) in the aging mouse brain. Additionally, they demonstrate that #TREM2 is required for both the development and function of myelin clearing WAM. cell.com/neuron/fulltex…

Over the #RareDiseaseDay weekend, the Vigil team will participate in seerarerun's virtual race. All proceeds and donations will go to NORD NORD. To find out more and register: runsignup.com/Race/NC/Chapel…

Yesterday in observance of #RareDiseaseDay, the Vigil team and their families met up for the seerarerun virtual race to support NORD. Rare is many. Rare is proud. Rare is strong. #VigilantForYou

Vigil is proud to recognize International Women's Day! We celebrate our accomplished women and those who #ChooseToChallenge gender based stereotypes in STEM. A challenged world is an alert world. #IWD2021

Thank you to Stifel’s Paul Matteis for a productive conversation with our CEO Ivana_VigilNeuroCEO in the 3rd Annual CNS Day Fireside Chat. “Microglia biology and neuroimmunity are rapidly becoming the new frontier of CNS drug discovery.” #vigilantforyou

Our CEO, Ivana Magovčević-Liebisch, will speak on Vigil's mission to harness the power of microglia in treating neurodegenerative diseases at Jefferies virtual healthcare conference. Sign up to watch live on Jun 4 at 9:30 EST or view the recording later: wsw.com/webcast/jeff17…

We’re thrilled to celebrate our #IPO by ringing the Nasdaq closing bell this afternoon! Going public is a major step for us in advancing our mission of changing the world, one protein at a time. #absci $ABSI

We are thrilled to welcome an all-star group of investors to our $90 million Series B led by Vida Ventures. We are also proud to announce #ALSP as the first indication for VGL101. #TREM2 #CSF1R #Alzheimers #Boston #Biotech #Raredisease #VigilantForYou bwnews.pr/3k7l32C

The first subject has been enrolled in our #ALSP natural history study. Thank you to the patients, families, and sites who will help us increase knowledge of ALSP so that we may advance the development of VGL101 as a potential treatment bwnews.pr/3tG2IOJ #TREM2 #CSF1R

Today we celebrate Vigil’s first day of trading on the Nasdaq. Together, we are building a better tomorrow for patients with neurodegenerative diseases. Thank you to everyone who has helped us reach this milestone. $VIGL #IPO

Our journey is just beginning. We are unyielding in our quest to realize the power of #microglia to improve the lives of patients, caregivers and families. Because patients cannot wait.

Thank you Luke Timmerman for sharing our call to support reproductive healthcare. “By signing this letter, we as individuals and organizations commit to these calls to action, and to maintaining continuous vigilance in our collective fight to improve human health for all.”